Anticoagulation Update: DOACs, VTE Guidelines, “Bridging ... · Candidates for a DOAC therapy: Special populations • Evidence is limited • Patients

Anticoagulation Update: DOACs, VTE Guidelines, “Bridging”

and iCentra (whew!)

Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical Center Professor of Medicine University of Utah School of Medicine

Clinical Learning Day 2016

Disclosures

• Investigator initiated grant recipient: Bristol-

Myers-Squibb (paid to Intermountain Healthcare)

• Panelist American College of Chest Physicians (ACCP) Clinical Practice Guideline: Antithrombotic therapy for venous thromboembolic disease (AT10)

Objectives • DOAC limitations & use in routine clinical care

– Special populations

• AT10 Updates: Venous Thromboembolism • Anticoagulation procedural interruption (“bridging”)

– Warfarin – DOACs

• Why & how to manage anticoagulation in iCentra

The Direct Oral Anticoagulants

The Direct Oral Anticoagulants Rivaroxaban Apixaban Edoxaban Dabigatran

BRAND NAME PHARMACEUTICAL

Xarleto™ Bayer

Eliquis™ BMS & Pfizer

Savaysa™

Daiichi Sankyo Pradaxa™

Boehringer Ingelheim

TARGET Factor Xa Factor Xa Factor Xa Factor IIa

BIOAVAILABILITY (%) ~80 ~50 62 6–7

TIME TO PEAK (h) 2–3 1–2 1-2 1.5

HALF-LIFE (h) 9-13 8-15 9-10 12-14

RENAL EXCRETION (%) 33 25 35 >80

EFFECT ON aPTT/PT* 1.8/2.6 1.2/~2 yes 2.3/NR

EFFECT ON Xa 68% NR NR No Effect

DRUG INTERACTIONS CYP3A4 IND/INH CYP3A4 INH P-gp INH/CYP3A4 Verapamil/rifampin

Derived from: Crowther. Blood. 2008;111:4871-4879; Garcia, D. Blood. 2010;115:15-20; http://www.eliquis.com/PDF/ELIQUIS%20%C2%AE%20(apixaban)%20SmPC.pdf Schulman Thromb Haemost 2014; 111:

http://www.eliquis.com/PDF/ELIQUIS%20%C2%AE%20(apixaban)%20SmPC.pdf

Choosing a DOAC vs. warfarin in AF

Ruff CT et al. Lancet 2014; 383: 955–62

Presenter

Presentation Notes

There was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based TTR was less than 66% than when it was 66% or more (0·69, 0·59–0·81 vs 0·93, 0·76–1·13; p for interaction 0·022). The relative reduction of major bleeding that was observed among the DOACs when compared with warfarin was no longer observed when the comparator was warfarin in centers with TTR achieved >/=66%.

Choosing a DOAC vs. warfarin in AF

Ruff CT et al. Lancet 2014; 383: 955–62 *TTR > 66%

*

Presenter

Presentation Notes

There was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based TTR was less than 66% than when it was 66% or more (0·69, 0·59–0·81 vs 0·93, 0·76–1·13; p for interaction 0·022). The relative reduction of major bleeding that was observed among the DOACs when compared with warfarin was no longer observed when the comparator was warfarin in centers with TTR achieved >/=66%.

AT10 Summary of evidence: Recurrent VTE

QUESTION: Should a DOAC or warfarin be used for acute and long-term treatment of VTE ? Quality assessment Summary of Findings

NOAC n (studies)

Risk of bias Overall quality of evidence

Study event rates (%) Relative effect

(95% CI)

Anticipated absolute effects With LMWH

and VKA With NOAC Risk w/

LMWH &VKA

Risk difference with NOACs

(95% CI)

Recurrent VTE RIVAROXABAN 8281 (2 studies)

no serious risk of bias

⊕⊕⊕⊝ MODERATE

due to imprecision

95/4131 (2.3%)

86/4150 (2.1%)

RR 0.90 (0.68 to 1.2)

23 per 1000 2 fewer per 1000 (from 7 fewer

to 5 more)

DABIGATRAN 5107 (2 studies)



due to imprecision

55/2554 (2.2%)2

60/2553 (2.4%)

RR 1.12 (0.77 to

1.62)

22 per 1000 3 more per 1000 (from 5 fewer to 13 more)

APIXABAN 5244 (1 study)



due to imprecision

71/2635 (2.7%)

59/2609 (2.3%)

RR 0.84 (0.6 to 1.18)


to 5 more)

EDOXABAN 8240 (1 study)



due to imprecision

146/4122 (3.5%)3

130/4118 (3.2%)

RR 0.83 (0.57 to

1.21)


to 7 more)

Presenter

Presentation Notes

BACKGROUND: Key Point: Each of the next 3 slides summarizes the quality of evidence and findings of the studies that compare each NOAC considered with usual care for patient-important outcomes. Key Point: Inform all that the next 3 slides are formatted similarly. Take a few seconds and walk through the setup of the slide (NOACs on the Left column, quality of evidence on the left, rates of the outcome in the middle for the NOAC and comparator, and the relative risk and risk difference for the outcome of on the right) PRESENTER: This evidence compares each NOAC with usual care for the patient-important outcome of Recurrent VTE. Highlight the few studies yet large size. Highlight that the overall quality of the evidence is moderate due to imprecision (see Glossary in the APPENDIX slides for definitions as necessary) however the risk of bias is thought to be low. Highlight that recurrent VTE is rare among patients on VKA and that for each NOAC studied, the relative risk for recurrent VTE did not differ among patients randomized to NOAC or VKA. Key Point: For the patient-important outcome of Recurrent VTE the NOACs did not differ from usual care. Suggested time to spend presenting this slide: 2 ½ minutes. AT10 Reference: Page 31-35; e-Tables 5-8

From the clinical trials:

• Need for thrombolytic therapy • An indication for anticoagulation for which no DOAC approval exists • High risk of bleeding • Significant liver disease (hepatitis, cirrhosis, or AST/ALT ≥ 3x ULN) • Creatinine clearance 30 mL/min (apixaban threshold was 25 mL/min) • Aspirin use (100 mg/day) • Concomitant use of interacting medications • Uncontrolled hypertension

Who is not?

Who is a candidate for a DOAC therapy to treat VTE?

Schulman S (2013) N Engl J Med 368:709–718. EINSTEIN Investigators (2010) N Engl J Med 363:2499–2510. Agnelli G (2013) N Engl J Med 368:699–708. Schulman S (2009) N Engl J Med 361:2342–2352. Schulman S (2014) Circulation 129:764–772 EINSTEIN–PE Investigators (2012). N Engl J Med 366:1287–1297. Agnelli G (2013) N Engl J Med 369:799–808. Hokusai-VTE Investigators (2013) N Engl J Med 369:1406–1415.

Presenter

Presentation Notes

PRESENTER: 2B recommendation (weak with moderate quality evidence) Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 31-35; e-Tables 5-8

From the school of hard knocks:

• Patients who struggle with compliance (unless related to transportation for INRs) • Warfarin is likely favorable to allow ascertainment of and

anticoagulant effect

• Financial barriers to longitudinal compliance • After 1.1 year f/u <50% prescribed DOAC picked up adequate

drug to cover 80% days

Who is not?

Who is a candidate for a DOAC therapy to treat VTE?

Kearon C AT10 Chest 2016; Yao, X Chest Physician Vol. 11, No. 2 Feb. 2016

DOAC therapy: Special populations

Pregnancy

Candidates for a DOAC therapy: Special populations

XARELTO-PM-ENG-10JUL2014-172618.pdf. http://www.bayer Boehringer Ingelheim Canada Ltd (2014) Pradaxa product monograph. http://www.boehringeringelheim.ca; images from: colorbox.com; dailykos.com; Bapat P et al.. J Thromb Haemost 2016; 14: 1436–41.; Bapat P etal. Obstet Gynecol 2014; 123: 1256; 15 Bapat P etal. Am J Obstet Gynecol 2015; 213: 710.e1–6.

+ Dabigatran or rivaroxaban =

• Apixaban has no human data in pregnancy, but showed no maternal or fetal harm in animal studies • Ex vivo drug concentration across placenta F:M ratio 0.9

• Edoxaban animal studies demonstrated no fetal harm

• DOAC excretion in breast milk is not known.

Presenter

Presentation Notes

Animal studies of dabigatran and rivaroxaban demonstrated pregnancy loss and fetal harm Ex vivo drug dabigatran across placenta F:M ratio 0.33 Ex vivo drug rivaroxaban across placenta F:M ratio 0.69

http://www.boehringeringelheim.ca/

Pregnancy


dailykos.com

Presenter

Presentation Notes

Animal studies of dabigatran and rivaroxaban demonstrated pregnancy loss and fetal harm

Extremes of weight


• Evidence is limited • Patients <50–60 kg were 2–13 % of DOAC study populations &

16 % of patients were >100 kg • 1 meta-analysis showed that for patients >100kg recurrent VTE

risk was 0.9 (95% CI 0.77-1.06) • Dabigatran does not appear to be affected by extremes of weight • Weight may affect kinetics of anti-Xa’s but the clinical significance

is unknown. • ISTH and AC Forum suggest against use based on PK/PD in obese

Schulman NEJM 2009; EINSTEIN Investigators NEJM 2010; AMPLIFY NEJM 2013; HOKUSAI NEJM 2013; Stangier DJ Clin Pharmacokinet 2008; Frost J. thromb Haemost 2009; Upreti VV 2013 Br J Clin Pharmacol; Kubitza D 2007 J Clin Pharmacol; clipartbest.com; van Es Blood. 2014; Martin K etal. J Thromb Haemost 2016; 14: 1308–13.; Burnett etal. J Thromb Thrombolysis (2016) 41:206–232

Presenter

Presentation Notes

Low weight patients (<50 kg) have a 20–30 % increased exposure to apixaban compared to normal weight subjects whereas patients >120 kg have a 23–30 % lower exposure to apixaban compared to normal weight subjects Gender, age, race or extremes of weight (<50 or>110 kg) do not significantly impact dabigatran pharmacology (Stangier J. 2009 CATH 15(Suppl 1):9S–16S) AC FORUM: BMI > 35 or >120 kg ISTH: BMI of > 40 kg or a weight of > 120 kg

Extremes of weight


dailykos.com

Presenter

Presentation Notes

Low weight patients (<50 kg) have a 20–30 % increased exposure to apixaban compared to normal weight subjects whereas patients >120 kg have a 23–30 % lower exposure to apixaban compared to normal weight subjects Gender, age, race or extremes of weight (<50 or>110 kg) do not significantly impact dabigatran pharmacology (Stangier J. 2009 CATH 15(Suppl 1):9S–16S)

Elderly


• Evidence from a meta-analysis of the Phase 3 trials studying VTE

• Pooled DOAC vs. VKA for age ≥ 75 years for recurrent VTE or VTE-related death: HR 0.56 (95% CI 0.38-0.82) p=0.003

• Pooled DOAC vs. VKA for age ≥ 75 years for Major bleeding: HR 0.49 (95% CI 0.25-0.96) p=0.04

van Es N. Blood. 2014; pintrest.com

Presenter

Presentation Notes

Additionally, elderly patients have a 32 % increase in AUC of apixaban compared to younger subjects. Gender, age, race or extremes of weight (<50 or>110 kg) do not significantly impact dabigatran pharmacology (Stangier J. 2009 CATH 15(Suppl 1):9S–16S)

Elderly


van Es N. Blood. 2014; pintrest.com

Presenter

Presentation Notes

Additionally, elderly patients have a 32 % increase in AUC of apixaban compared to younger subjects. Gender, age, race or extremes of weight (<50 or>110 kg) do not significantly impact dabigatran pharmacology (Stangier J. 2009 CATH 15(Suppl 1):9S–16S)

Thrombophilias


• Evidence is limited • Patients with thrombophilias comprised 2-18% of those

enrolled in DOAC trials

• Post-hoc dabigatran data shows no difference in recurrent VTE

• Exception: APS--3 ongoing studies • RAPS (Canada), TRAPS (Italy), ASTRO-APS (USA)

Schulman S (2013) N Engl J Med 368:709–718. EINSTEIN Investigators (2010) N Engl J Med 363:2499–2510. Agnelli G (2013) N Engl J Med 368:699–708. Schulman S (2009) N Engl J Med 361:2342–2352. Schulman S (2014) Circulation 129:764–772 EINSTEIN–PE Investigators (2012). N Engl J Med 366:1287–1297. Agnelli G (2013) N Engl J Med 369:799–808. Hokusai-VTE Investigators (2013) N Engl J Med 369:1406–1415; Schulman S et al (2014) ASH 56th annual meeting Dec 2014, session 332 abstract 1544

Presenter

Presentation Notes


Thrombophilias


dailykos.com

Presenter

Presentation Notes


Thrombophilias


APS =

dailykos.com

Presenter

Presentation Notes


Cancer


• No dedicated RCT evidence for cancer patients exists • Systematic reviews of the cancer subgroup from the clinical

trials suggest DOACs are similar to VKA for VTE recurrence risk reduction and no difference in MB/CRNMB

• 1 meta-analysis suggested for VTE recurrence RR 0.57 (95% CI

0.36-0.91; p=0.02)

Schulman S 2013 NEJM EINSTEIN Investigators 2010 NEJM ; Agnelli G 2013 NEJM; Schulman S 2009 NEJM; Schulman S 2014 Circulation; EINSTEIN–PE Investigators 2012 NEJM; Agnelli G 2013 NEJM; Hokusai-VTE Investigators 2013 NEJM; Castellucci LA. 2014 JAMA; Carrier M. 2014 Thromb Res; Vedovati MC. 2015 Chest; Di Minno MN. 2014 J Thromb Haemost; Franchini M.2015 Thromb Res

Presenter

Presentation Notes


Cancer


Schulman S 2013 NEJM EINSTEIN Investigators 2010 NEJM ; Agnelli G 2013 NEJM; Schulman S 2009 NEJM; Schulman S 2014 Circulation; EINSTEIN–PE Investigators 2012 NEJM; Agnelli G 2013 NEJM; Hokusai-VTE Investigators 2013 NEJM; Castellucci LA. 2014 JAMA; Carrier M. 2014 Thromb Res; Vedovati MC. 2015 Chest; Di Minno MN. 2014 J Thromb Haemost; Franchini M.2015 Thromb Res; va Es 2015; Kearon C AT10 2016

Presenter

Presentation Notes


• AT10 states that “For VTE and cancer, we suggest LMWH over VKA

(Grade 2B), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C).”

• No comparison of DOAC with LMWH to date • 5 ongoing trials (rivaroxaban=2, apixaban=2, edoxaban=1)

clinicaltrials.gov accessed 12 MAR 2016

Cancer


Kearon C AT10 2016

Presenter

Presentation Notes


Cancer


dailykos.com

Presenter

Presentation Notes


Choosing between DOACs: Summary

Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban

Cost +++ + + + + Compliance +++ + ++ + ++ Bleeding risk

+ ++ ++ +++ +++ Renal Dysfunction

+++ + + ++ + QOL + ++ +++ ++ +++ +: Less favorable +++: More favorable

Treatment updates for Venous Thromboembolism

Kearon C. CHEST 2016; 149(2):315-352

Evaluation of Individuals with Pulmonary Nodules: General Approach

Of the 53 recommendations in this update, 20 (38%) are strong recommendations (Grade 1) and none are based on high quality (Grade A) evidence. AT LGM represents the first endeavor to transition to a continually updated “Living Guideline” with a format designed to facilitate updates as new evidence becomes available.

AT living guideline model


AT10 Guideline Statement:

AT10 Choice of anticoagulant for long-term treatment of DVT and PE: DOAC vs. warfarin

In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest apixaban or edoxaban or rivaroxaban or dabigatran over VKA therapy (Grade 2B). Remarks: Acute therapy with parenteral anticoagulation is given before dabigatran and edoxaban.

Kearon C. Chest. 2016. doi:10.1016/j.chest.2015.11.026

For the first time an alternative to usual care with low molecular weight heparin and warfarin has been suggested for the long-term treatment of PE and DVT.

Presenter

Presentation Notes

BACKGROUND: By way of brief orientation, VKA is vitamin K antiagonist(«warfarin») and NOAC refers to the «non-vitamin K oral antcoagulants» and LMWH is «low molecular weight heparin» Key Point: For ease of discussion we will refer to the treatment of acute VTE as «long-term» treatment (which implies initial 3 months). We imply that initial therapy for acute VTE with warfarin (and select DOACs as studied) requires initial parenteral anticoagulation. PRESENTER Read the guideline statement Key Point: For the first time an alternative to usual treatment with LMWH + warfarin has been suggested for long-term treatment (first 3 months) of VTE. This is a weak recommendation. Let’s review the evidence and decision-making that is supportive of this statement. Suggested time to spend presenting this slide: 60 seconds. _______________________________________________________________________________________________________________________ Citations (Prandoni et al Haematologica 2008; 93:1432-1434.)�Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA. 2014;312(11):1122-1135.


Recommended therapy for VTE takes into consideration efficacy, safety, and burden of treatment (can also include cost). Is there evidence to recommend 1 DOAC over another? DOACs have not been compared head-to-head for patient-important outcomes. Based on indirect comparisons these outcomes appear to be similar with all of the NOACs Individual patient characteristics (including cost and insurance coverage) will likely drive choice of anticoagulant for the initial 3 months of therapy

AT10 Choice of anticoagulant for long-term treatment of DVT and PE: DOAC vs. warfarin

Presenter

Presentation Notes

BACKGROUND: The NOACs have not been compared head-to-head. This slide summarizes a suggested overall approach. QUESTION: So why did the panelists suggest NOACs over warfarin if no difference in patient-important outcomes was observed? PRESENTER: Walk through slide Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 31-35; e-Tables 5-8


In patients with subsegmental PE (no involvement of more proximal pulmonary arteries), no proximal DVT in the legs, and a low risk for recurrent VTE (see text), we suggest clinical surveillance over anticoagulation (Grade 2C).

Whether to Anticoagulate Subsegmental Pulmonary Embolism NEW TOPIC!

Kearon C. CHEST 2016; 149(2):315-352

Presenter

Presentation Notes

PRESENTER: Read guideline statement Highlight that this is a low grade (2C) recommendation Lets discuss the evidence (or lack there-of) that led to this Guideline Statement Suggested time to spend presenting this slide: 15 seconds. AT10 Reference: Page 68-73; e-Tables 18

Evaluation of Individuals with Pulmonary Nodules: General Approach Definition: Subsegmental PE (SSPE) refers to PE that is confined to the subsegmental pulmonary arteries (and may occur bilaterally). SSPE has become important because improvements in computerized tomography pulmonary angiography (CTPA) have increased how often subsegmental PE is diagnosed. Now SSPE constitutes about 10% of all PE cases.


Presenter

Presentation Notes

BACKGROUND: Describe what SSPE is. Report why SSPE has become an issue, and why AT10 chose to address SSPE. PRESENTER: Define SSPE. Key Point: prevalence of SSPE has increased because of enhanced imaging Suggested time to spend presenting this slide: 15 seconds. AT10 Reference: Page 62-65 ___________________________________________________ BACKGROUND LITERATURE: Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ. 2013;347:f3368. Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost. 2012;10(8):1486-1490. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost. 2012;18(1):20-26. den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122(7):1144-1149; quiz 1329.


No RCTs exist to direct treatment of SSPE however high quality evidence supports anticoagulation for treatment of larger PE Whether the risk of progressive or recurrent VTE is high enough to justify anticoagulation in patients with SSPE is uncertain


Presenter

Presentation Notes

Scant evidence exists from retrospective studies suggesting that SSPE may be comparatively benign (analogous to isolated distal DVT; Carrier n=60) however also perhaps with a comparative increased risk for recurrence; den Exter 2013) QUESTION: What evidence exists regarding the treatment of SSPE? PRESENTER: The strength and quality of the evidence to inform this guideline statement is low Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 62-65 _______________________________________________________ RCT: randomized control trial VTE: venous thromboembolism (the aggregate of DVT + PE) Citations and references: Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ. 2013;347:f3368. Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost. 2012;10(8):1486-1490. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost. 2012;18(1):20-26. den Exter PL, van Es J, Klok FA, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122(7):1144-1149; quiz 1329.


What considerations are important upon weighing SSPE treatment options?

1. Consider certainty of true thrombosis being present (evaluate

likelihood of observed thrombosis being a false positive result) SSPE is more likely a true-positive if…

CTPA characteristics (quality, multiple defects, multiple projections, etc.)

Patients are symptomatic (as opposed to PE being an incidental finding)

There is a high clinical pre-test probability for PE

Elevated D-Dimer that’s otherwise unexplained


Presenter

Presentation Notes

BACKGROUND: AT10 suggests a systematic approach to considering anticoagulation treatment for SSPE. QUESTION: On slide �PRESENTER: Key Point: Consider if the observed SSPE is thought to be true disease or rather a false positive result. (read through the table) Suggested time to spend presenting this slide: 2 minutes AT10 Reference: Page 62-65


What considerations are important upon weighing SSPE treatment options?

2. Assess the patient for risk factors for progressive thrombosis and risk of anticoagulation.

Favors Anticoagulation Favors No Anticoagulation Active cancer (particularly if metastatic or on chemotherapy)

High bleeding risk

No reversible VTE risks (e.g. recent surgery) Patient prefers to avoid anticoagulation

Marked symptoms without another cause Patient prefers anticoagulation Hospitalized or immobilized


Presenter

Presentation Notes

BACKGROUND: Individual patient risk for progression of thrombosis and bleeding complications should be considered. QUESTION: On slide PRESENTER Key Point: Assess the patient for risk factors for progressive thrombosis as these being present would influence decision-making Walk through those patient characteristics that may favor anticoagulation or not. Suggested time to spend presenting this slide: 1 minute. AT10 Reference: Page 62-65

What additional testing and follow-up is recommended if the decision is to not anticoagulate SSPE?

Additional testing recommended Additional follow-up

Bilateral US to exclude proximal DVT of the legs

Assure patient literacy surrounding signs and symptoms of progressive thrombosis

Exclude DVT in other high risk locations (e.g. upper extremities if a central line is present)

Perform one or more follow-up US of the legs to detect (and then treat) evolving proximal DVT


Presenter

Presentation Notes

BACKGROUND: Highlight that if it decided to withhold anticoagulation among patients with isolated SSPE, then additional testing and follow-up is recommended QUESTION: On slide PRESENTER: Key Point: DVT that would influence decisionmaking should be excluded. (Walk through the recommendations if AC is withheld) � PRESENTER PEARL: Serial testing for proximal DVT has been shown to be a safe management strategy in patients with suspected PE who have non-diagnostic ventilation-perfusion scans, many of whom are expected to have subsegmental PE (1,2,3) Suggested time to spend presenting this slide: 1 minute. AT10 Reference: Page 62-65 _____________________________________________ BACKGROUND: �If withholding AC is considered, then bilateral ultrasound examinations to exclude proximal DVT of the legs (and DVT should also be excluded in other high-risk locations, such as in upper extremities with central venous catheters). If a decision is made to not AC, then doing one or more follow-up ultrasound examinations of the legs to detect (and then treat) evolving proximal DVT is an option. Citation of additional references: Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next step? J Thromb Haemost. 2012;10(8):1486-1490. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options. Clin Appl Thromb Hemost. 2012;18(1):20-26. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med. 1998;129(12):1044-1049

SUMMARY With a weak recommendation based on low quality evidence (Grade 2C), clinical surveillance is suggested over anticoagulation in patients with isolated subsegmental PE If clinical surveillance is chosen, it should be assured that no proximal DVT in the legs exists, and that the patient is at a low risk for recurrent VTE Upon clinical surveillance perform serial ultrasound of the legs to detect evolving DVT (e.g. repeating ultrasound weekly x 2 weeks)


Presenter

Presentation Notes

PRESENTER: Key Point: Present qualifying statements associated with refraining from anticoagulation of SSPE Suggested time to spend presenting this slide: 1 minute. AT10 Reference: Page 62-65

Management of Recurrent Venous Thromboembolism on Anticoagulant Therapy New TOPIC!

In patients who have recurrent VTE on VKA therapy (in the therapeutic range) or on dabigatran, rivaroxaban, apixaban or edoxaban (and are believed to be compliant), we suggest switching to treatment with LMWH at least temporarily (Grade 2C).


Kearon C. CHEST 2016; 149(2):315-352

Presenter

Presentation Notes

BACKGROUND: This recommendation is a new topic in AT10 that has not been previously discussed. PRESENTER: Read slide Weak recommendation based on low quality evidence Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 81-84

Risk factors for recurrent VTE while on anticoagulant therapy can be divided into two broad categories:

(1) Treatment factors (2) Patient intrinsic risk of recurrence


Presenter

Presentation Notes

QUESTION: What risk factors exist for recurrent VTE while on therapeutic anticoagulation? PRESENTER: Present slide Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 81-84

TREATMENT FACTORS Important initial considerations when assessing for

recurrent VTE on anticoagulant therapy (1) Was the patient adherent (2) Was warfarin sub-therapeutic (3) Was anticoagulant therapy prescribed correctly (4) Was the patient taking a NOAC and a drug that reduced anticoagulant effect (5) Had anticoagulant dose been reduced (drugs other than warfarin)


Presenter

Presentation Notes

BACKGROUND: PRESENTER: The most frequent cause of recurrent thrombosis surrounds patient compliance (pt literacy, cost, etc.) Review approach to recurrent VTE Suggested time to spend presenting this slide: 1 minute. AT10 Reference: Page 81-84

INTRINSIC PATIENT RISK FACTORS FOR RECURRENCE Important considerations when assessing for

recurrent VTE on anticoagulant therapy (1) Active cancer (occult disease should always be considered)

(2) Antiphospholipid Syndrome

i. Associated with recurrence ii. LA can interfere with the INR (spurious results)

(3) Concomitant use of medications that increase risk of thrombosis


Presenter

Presentation Notes

BACKGROUND: Individual patient characteristics can provide insight into the cause of recurrent thrombosis. PRESENTER: Emphasis on cancer’s influence Suggested time to spend presenting this slide: 1 minute. AT10 Reference: Page 81-84

SUMMARY If a patient is on warfarin, then it is recommended to switch to treatment-dose LMWH If a patient is on LMWH, then it is recommended to increase the dose by about 25% If anticoagulant intensity cannot be increased because of risk of bleeding, an IVC can be inserted to prevent PE This is a least favorable option of last resort


Presenter

Presentation Notes


Aspirin for extended treatment VTE?

Aspirin for the secondary prevention of VTE

In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, we suggest aspirin over no aspirin to prevent recurrent VTE (Grade 2B)


Kearon C. CHEST 2016; 149(2):315-352

Presenter

Presentation Notes

BACKGROUND: This recommendation is a new topic in AT10 that has not been previously discussed. PRESENTER: Read slide Weak recommendation based on low quality evidence Suggested time to spend presenting this slide: 30 seconds. AT10 Reference: Page 81-84

Quality Evidence (GRADE)

Hazard Ratio

Difference Per 1,000

VTE

Major Bleeding

Mortality

Studies: 2 Participants: 1,224


Presenter

Presentation Notes


• Anticoagulants reduce VTE >90% • DOACS suggested if unprovoked & low risk bleeding • Bleeding may be similar with ASA & DOACs

SUMMARY

Unprovoked proximal DVT or PE and stop AC & no contraindication then aspirin over no aspirin (Grade 2B)


Bridge therapy

www.bridge1980.com; www.istockphoto.com; en.wikipedia.org

http://www.bridge1980.com/

http://www.istockphoto.com/

https://en.wikipedia.org/wiki/Stick_figure

Anderson M Clev. Clin J Med, 2014, 8; 629;

About 2.5M Americans require long-term anticoagulation

About 10% require interruption annually

Warfarin interruption for procedures “Bridging”

Bridge Trial: Atrial Fibrillation • RDBPCT 1884 pts. with AF Dalteparin or Placebo

– From 3 days before until AM before the procedure and then for 5-10 days after

– Demographics: mean age 72; 97.2% with CHADS ≤ 4 – Time to first post-procedure dose: 53h (H) 21h (L) – Mean # Post-Procedure doses: 16

Douketis JD etal. NEJM online 22 June 2014

Presenter

Presentation Notes

90% white 2.5% with CHADS 5 35% on asa (60% no interruption; 28% >7d interruption 10% < 7d interruption)

Warfarin interruption for procedures “Bridging” Bridge Trial

• Results – The incidence of arterial TE 0.4% in the no-bridging

group and 0.3% in the bridging group (95% CI −0.6-0.8; P = 0.01 for noninferiority).

– The incidence of major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group RR 0.41 (95% CI 0.20-0.78; p= 0.005 for superiority).

• Conclusion: Forgoing bridging in AF patients was noninferior to bridging for stroke and decreased the risk of major bleeding.

Douketis JD etal. NEJM online 22 June 2014

Presenter

Presentation Notes

90% white 2.5% with CHADS 5 35% on asa (60% no interruption; 28% >7d interruption 10% < 7d interruption)


Warehouse Study: VTE • Retrospective cohort study at Kaiser Colorado • 1187 pts. on indefinite anticoagulation for VTE

– Demographics: • mean age 66; 46% M • 56% DVT 44% PE • 79% “low risk for recurrence” at time of interruption • 98.7% with VTE ≥ 3 mo. prior • Procedures: GI Endo (37%) ortho (14%) spine (10%) abd sx (9%)

• Outcome: 30-d clinically relevant bleeding, recurrent VTE, and all-cause mortality.

Clark NP etal. JAMA Intern Med. Online May 26, 2015.

Presenter

Presentation Notes

90% white 2.5% with CHADS 5 35% on asa (60% no interruption; 28% >7d interruption 10% < 7d interruption) Recurrent Venous Thromboembolism Risk Stratification Category Criteria High: Acute VTE within past 3 mo; severe thrombophilia (deficiency of protein C, protein S, or antithrombin; antiphospholipid antibody syndrome; or multiple abnormalities) Medium: Acute VTE within past 3-12 mo; nonsevere thrombophilia (heterozygous factor V Leiden, prothrombin 20210 mutation, increased factor VIII activity); recurrent VTE; or active cancer Low: Acute VTE >12 mo previously; no other risk factors


Warehouse Study • Results

– There was no significant difference in the rate of recurrent VTE between groups (0 vs 3; P = .56).

– 30d bleeding in the bridge therapy and non–bridge groups occurred in 15 patients (2.7%) and 2 patients (0.2%), respectively (hazard ratio, 17.2; 95%CI 3.9-75.1).

• Conclusion: Bridge therapy was associated with an

increased risk of bleeding during warfarin interruption among VTE patients and is likely unnecessary for most.

Clark NP etal. JAMA Intern Med. Online May 26, 2015.

Presenter

Presentation Notes

90% white 2.5% with CHADS 5 35% on asa (60% no interruption; 28% >7d interruption 10% < 7d interruption) No deaths in either group

Anderson M Clev. Clin J Med, 2014, 8; 629;

Generally, interrupt 4-5 half-lives before HBR procedure

OK to interrupt 2-3 half-lives before LBR procedure

Half-life increases as renal function worsens

Pre-procedural interruption of DOACs

Adapted from Gladstone DJ Ann Intern Med. 2015;163:382-385.

Douketis J. Current Pharmaceutical Design, 2010, 16, 3436-3441

Why use warfarin decision-support?

Anticoagulation management: iCentra

Why Clinical Decision Support in iCentra? AT 9 Guideline “For dosing decisions during maintenance VKA therapy, we suggest using validated decision support (e.g. computerized programs) rather than no decision support.” Anticoagulation Forum “When determining warfarin doses during VTE treatment we suggest using computer-aided warfarin dosing programs over an ad hoc approach.”

Holbrook CHEST 2012; 141(2)(Suppl):e152S–e184S; Witt D etal. J Thromb Thrombolysis (2016) 41:187–205

Presenter

Presentation Notes

See periodically to assure renal fn is OK and bleeding/thrombosis risk is acceptable

CDS outcomes within Intermountain

Presenter

Presentation Notes

Computerized Decision Support observed outcomes

Time that the patient is taking warfarin

Pre-Post warfarin management with CAC CDS

Patient enrolled in

CAC

INRs before CDS

INRs after CDS

n=2591

Woller, SC et al. Clin Appl Thromb Hemost. 2015 Apr;21(3):197-20

Results

TTR=64% TTR=65.1%


Results: Secondary Outcomes

Major Complications

Percent Δ

p-value BEFORE CDS AFTER CDS

Events, n Events/

100 Pt. yrs. Events, n

Events/ 100 Pt. yrs.

PE 59 0.85 23 0.27 -68% <0.0001

VTE with hospitalization

96 1.38 47 0.56 -59% <0.0001

Stroke 2 0.02 1 0.01 NA 0.7365

Major Bleed 77 0.91 94 1.30 +30% 0.0106

ED visit 3831 55 2876 34 -38% <0.0001

Hospitalization 2943 42 2221 26 -44% <0.0001


Comprehensive Anticoagulation CDS in iCentra

• Initiation protocol

• Chronic protocol

• Bridging protocol

• DOAC Management*

*Coming soon….

Anticoagulation CDS in iCentra: workflow

Presenter

Presentation Notes

Access to the suite of AC management tools is available through the Anticoagulation workflow tab

Routine warfarin management in iCentra

Workflow for chronic anticoagulation management


Presenter

Presentation Notes

M.A fills out anticoagulation worksheet, after INR is documented, gathers information from the patient to update the Clinician summary report below.


Clinician summary report

Presenter

Presentation Notes

Clinician Summary report: this is what the MA brings to the MD to decide dosing and f/u


Presenter

Presentation Notes

M.A. documents any changes or to stay on current dose, Next INR Date from recommendations


Presenter

Presentation Notes

MA generates note


Patient Summary Report

Presenter

Presentation Notes

Patient Summary report to give after visit

Summary • DOAC limitations & use in routine clinical care

– Special populations

• AT10 Updates: Venous Thromboembolism • Anticoagulation procedural interruption

(“bridging”) – Warfarin – DOACs

• Why & how to manage anticoagulation in iCentra

QUESTIONS?

Documents

Anticoagulation Update: DOACs, VTE Guidelines, “Bridging ... · Candidates for a DOAC therapy: Special populations • Evidence is limited • Patients